| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6182793 | Gynecologic Oncology | 2014 | 6 Pages |
Abstract
Our multivariate model identified prior number of chemotherapy regimens, TFI, platinum sensitivity, and the presence of ascites as prognostic variables for OS in women with recurrent ovarian cancer treated with bevacizumab combined with chemotherapy. Our nomogram to predict five-year OS may be used to identify women who may benefit from bevacizumab and chemotherapy, but further validation is needed.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
R.A. Previs, K.S. Bevis, W. Huh, T. Tillmanns, L. Perry, K. Moore, J. Chapman, C. McClung, T. Kiet, J. Java, J. Chan, A. Alvarez Secord,